Elisabeth Ge de Vries

29PUBLICATIONS
177CO-AUTHORS
Medical physicsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersGene and molecular therapyMedical molecular engineering of nucleic acids and proteins
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (29)

|May 08, 2026
Tri-specific Humabody CB307 Targeting CD137, Prostate-specific Membrane Antigen, and Human Serum Albumin Whole-body Biodistribution Measured with 89Zr-CB307 PET.

|Feb 10, 2026
Author Correction: Whole-body CD8+ T-cell PET imaging in patients with large B-cell lymphoma before and during CD19-directed CAR T-cell therapy: a phase 2 study.

Janneke W de Boer, Kylie Keijzer, Jaap A van Doesum

|Nov 25, 2025
Whole-body CD8+ T-cell PET imaging in patients with large B-cell lymphoma before and during CD19-directed CAR T-cell therapy: a phase 2 study.

Janneke W de Boer, Kylie Keijzer, Jaap A van Doesum

|Nov 10, 2025
Early [18F]FDG PET/CT Response after a Single Dose of Anti-EGFR Therapy as a Predictive Biomarker for Treatment Benefit in Patients with Advanced Colorectal Cancer.

Sophie L Gerritse, Erik J van Helden, Anne I J Arens

|Sep 10, 2025
Upfront whole blood transcriptional patterns in patients receiving immune checkpoint inhibitors associate with clinical outcome.

S Hone Lopez, S Loipfinger, A Bhattacharya

|Mar 17, 2025
A Phase I Dose Escalation and Cohort Expansion Study of CB307, a Trispecific Humabody against PSMA, CD137, and Albumin in Patients with PSMA-Positive Solid Tumors.

Johann S de Bono, Anja Williams, Ignacio Melero

Pageof 5

Frequent Collaborators

7 joint publications

Marjolijn N Lub-de Hooge

7 joint publications

Adrienne H Brouwers

7 joint publications

Rudolf S N Fehrmann

5 joint publications

Arkajyoti Bhattacharya